GLP-1 Drugs & Alcohol Cravings: Research Explains Why
- Weight-loss medications like Ozempic adn Zepbound appear to lessen alcohol cravings, and new research suggests a mechanism: slowing the rate at which alcohol enters the bloodstream, diminishing its...
- Glucagon-like peptide-1 (GLP-1) drugs, commonly prescribed for weight loss and diabetes management, appear to slow the speed at which alcohol enters the bloodstream. This slower absorption reduces the...
- Researchers found that individuals taking GLP-1 medications experienced a less pronounced effect from alcohol consumption.
“`html
GLP-1 drugs May Reduce Alcohol’s Effects by Slowing Absorption, Study Finds
Table of Contents
Weight-loss medications like Ozempic adn Zepbound appear to lessen alcohol cravings, and new research suggests a mechanism: slowing the rate at which alcohol enters the bloodstream, diminishing its impact on the brain.
Published October 16, 2024, at 16:22:02
What the New Research Shows
Glucagon-like peptide-1 (GLP-1) drugs, commonly prescribed for weight loss and diabetes management, appear to slow the speed at which alcohol enters the bloodstream. This slower absorption reduces the intensity of alcohol’s effects on the brain, according to a new pilot study published Wednesday in the journal Scientific Reports.
Researchers found that individuals taking GLP-1 medications experienced a less pronounced effect from alcohol consumption. Essentially, the feeling of intoxication is lessened because the body processes alcohol more gradually.
Why This Matters: Understanding the Connection
the observation that drugs like Ozempic and Zepbound reduce alcohol cravings has puzzled doctors. This study provides a potential description, linking the drugs’ impact on gastric emptying - the rate at which food and liquids leave the stomach – to alcohol absorption. GLP-1 drugs are known to slow gastric emptying, which in turn slows the absorption of alcohol into the bloodstream.
“People who drink know there’s a difference between nursing a glass of wine and downing a shot of whiskey,” said researcher Dr. David Malcolm, from the Fralin Biomedical Institute at Virginia Tech, in a news release. “This study suggests GLP-1 medications may mimic the effect of sipping slowly, spreading out the alcohol’s impact over time.”
Study Details and Limitations
The pilot study involved a small number of participants. researchers measured blood alcohol concentrations after participants consumed alcohol while either taking a GLP-1 medication or a placebo. The results consistently showed lower and slower-rising blood alcohol levels in the GLP-1 group.
It’s notable to note that this is a pilot study, meaning the findings need to be confirmed by larger, more comprehensive research. Further inquiry is also needed to determine the clinical significance of these findings – how much of a reduction in alcohol’s effects is typical, and whether this could have implications for managing alcohol use disorder.